ORLANDO, Fla., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Recently, Innovus Pharmaceuticals, Inc., (OTCQB:INNV) announced that they had expanded distribution for their widening product line by adding 18 new distributors. The distributors include well-known brands like Sears and K-Mart, joining Innovus’s broad footprint in major retail like Walmart, Kroger, Pathmark, Drugstore, Meijer and others totaling thousands of stores in the US. The retail presence of its products seems to be shepherded by a very strong online presence through the Company’s own websites but also through most of the large players such as Walmart, Walgreens, Quest and many others. The presence of Innovus products on the retail shelf space next to products such as KY Jelly, Durex, Trojan and many others is very impressive for such a small company and a testimony to the value of its products.
In a market where revenue is often the leading metric in determining shareholder value and forecasting future success, adding additional sales channels is paramount. Adding 18 is significant. Inarguably, the more items on the shelves - whether virtual or literal - is a very good thing.
Moreover, for a company with a portfolio of specialized health products for men and women ranging from those addressing respiratory disease to those that assist with sexual wellness, widening the product footprint is imperative. Each shelf creates and furthers brand awareness, introducing the product line to new customers not yet acquainted with the Innovus product line.
Time and future Q’s and K’s will tell the story of Innovus’s traction and monetization in these new venues - as well as proving whether the exposure in these additional venues is indeed accretive to product acceptance and sales in existing venues.
Meanwhile, the company continues to develop more products for eventual sale in appropriate channels with two more potentially market disruptive products in the pipeline. With a vast distribution network waiting for these products at the other end of the proverbial pipeline, Innovus is a story worth watching.
About the Emerging Markets Report:
Emerging Markets Report is owned and operated by Emerging Markets Consulting, a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Innovus Pharma's Forward-Looking Safe Harbor: Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products (Zestra®, Zestra Glide®, EjectDelay®, Sensum+® , Vesele® and Androferti®) and to achieve its other development, commercialization and financial goals, whether the new distributors will continue to successfully market and sell our products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company which we may later sell before, during or after our dissemination of the Information, and make profits therefrom.
EMC has been paid 600,000 restricted shares of INNV. EMC is under contract to receive an additional 675,000 shares.